SEC Filings Government Disclosures Contracts + Permits Earnings + IPOs Treasury Yields ETF Explorer Short Volume Screener Stock Research Portfolio Lab

Privacy Policy Terms of Service About

HCM

$10.96+2.62%Nasdaq

HUTCHMED (China) Ltd

Market Cap

$14.9B

Sector

—

Industry

—

Exchange

Nasdaq

Key Metrics

P/E

4.1x

P/S (TTM)

3.5x

P/B

1.8x

Gross Margin

+38.7%

Op. Margin

-7.1%

Net Margin

+83.3%

ROE (TTM)

+37.0%

Rev Growth YoY

-13.0%

EPS Growth YoY

+1109.2%

Price Chart

Loading…

Signals

Insider Velocity

News

6

recent articles

No financial data available for HCM.

Company may not file with SEC or CIK is unresolved.

No Form 4 transactions on record.

Recent News

Reported Earlier, HUTCHMED Says Sovleplenib Shows Favorable Safety Profile With Fewer Grade 3 Adverse Events Than Placebo

Benzinga · 2026-06-12

Why HUTCHMED (China) Limited (HCM) Is Gaining Attention After China Biotech Re-Rating

Yahoo · 2026-06-02

HSBC CEO Pitches HK Clients, Hires More Bankers After Setbacks

Yahoo · 2026-05-31

HUTCHMED and Innovent Jointly Announce NMPA Approval for ELUNATE® (Fruquintinib) in Combination with TYVYT® (Sintilimab Injection) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

Yahoo · 2026-05-21

Informational purposes only, not investment advice.

Innovent and HUTCHMED Jointly Announce NMPA Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Patients with Locally Advanced or Metastatic Renal Cell Carcinoma

Yahoo · 2026-05-21

HUTCHMED And Innovent Biologics Announce That The Joint New Drug Application For The Combination Of Elunate And Tyvyt Has Been Granted Approval By The China National Medical Products Administration

Benzinga · 2026-05-21